MedTrace Logo

TCR-Redirected T Cells Therapy in Patient With HBV Related HCC

NCT03899415 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-04-10

No results posted yet for this study

Summary

This is a single center. single arm, open-label study to determine the safety and clinical benefit of TCR-redirected T cell therapy in patient with HBV related HCC post hepatectomy or radiofrequency ablation.

Conditions

Interventions

BIOLOGICAL

TCR redirected T cells

HBV antigen specific TCR redirected T cell Infusions. Subjects will receive 1x10\^4 - 5x10\^6 TCR redirected T cells by IV infusion.

Sponsors & Collaborators

  • Lion TCR Pte. Ltd.

    collaborator INDUSTRY

  • Beijing 302 Hospital

    lead OTHER

Principal Investigators

  • Fusheng Wang, MD · Beijing 302 Hospital of China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-20
Primary Completion
2022-06-01
Completion
2024-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03899415 on ClinicalTrials.gov